VXLLF (Vaxil Bio) Cyclically Adjusted FCF per Share: $-0.44 (As of Mar. 2026)


VXLLF Vaxil Bio Ltd VXLLF
36 GF Score
Price $0.04
! 2 Warning Signs
View Full Analysis

What is Vaxil Bio Cyclically Adjusted FCF per Share?

Vaxil Bio VXLLF 36 Cyclically Adjusted FCF per Share is $-0.44 as of Mar. 2026. GuruFocus rates VXLLF with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Vaxil Bio's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.026. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.44 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 35.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 37.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Vaxil Bio was 46.20% per year. The lowest was 35.70% per year. And the median was 40.65% per year.

As of today (2026-07-05), Vaxil Bio's current stock price is $0.0366. Vaxil Bio's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-0.44. Vaxil Bio's Cyclically Adjusted Price-to-FCF of today is .


Vaxil Bio  (OTCPK:VXLLF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Vaxil Bio Cyclically Adjusted FCF per Share Related Terms


Vaxil Bio Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Vaxil Bio's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxil Bio Cyclically Adjusted FCF per Share Chart

Vaxil Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.25 -3.02 -0.94 -0.67 -0.47

Vaxil Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.66 -0.05 -0.24 -0.47 -0.44

VXLLF vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Vaxil Bio's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxil Bio Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxil Bio's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Vaxil Bio's Cyclically Adjusted Price-to-FCF falls into.


VXLLF
36GF Score
Vaxil Bio Ltd VXLLF
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxil Bio Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vaxil Bio's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.026/132.2600*132.2600
=-0.026

Current CPI (Mar. 2026) = 132.2600.

Vaxil Bio Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.460 102.002 -0.596
201609 -0.293 101.765 -0.381
201612 -0.211 101.449 -0.275
201703 -0.218 102.634 -0.281
201706 -0.216 103.029 -0.277
201709 -0.259 103.345 -0.331
201712 -0.076 103.345 -0.097
201803 -0.263 105.004 -0.331
201806 -0.073 105.557 -0.091
201809 -0.067 105.636 -0.084
201812 -0.045 105.399 -0.056
201903 -0.091 106.979 -0.113
201906 -0.089 107.690 -0.109
201909 -0.044 107.611 -0.054
201912 -0.028 107.769 -0.034
202003 -0.060 107.927 -0.074
202006 -0.149 108.401 -0.182
202009 -0.095 108.164 -0.116
202012 -0.164 108.559 -0.200
202103 -0.102 110.298 -0.122
202106 -0.094 111.720 -0.111
202109 -0.086 112.905 -0.101
202112 -0.036 113.774 -0.042
202203 -0.080 117.646 -0.090
202206 -0.033 120.806 -0.036
202209 -0.043 120.648 -0.047
202212 -0.049 120.964 -0.054
202303 -0.044 122.702 -0.047
202306 -0.077 124.203 -0.082
202309 -0.013 125.230 -0.014
202312 -0.019 125.072 -0.020
202403 -0.005 126.258 -0.005
202406 -0.018 127.522 -0.019
202409 -0.012 127.285 -0.012
202412 -0.015 127.364 -0.016
202503 -0.012 129.181 -0.012
202506 -0.014 129.892 -0.014
202509 -0.007 130.290 -0.007
202512 -0.007 130.370 -0.007
202603 -0.026 132.260 -0.026

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.44 mean?
Vaxil Bio (VXLLF) has a Cyclically Adjusted FCF per Share of $-0.44 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Vaxil Bio and its competitors.
Is Vaxil Bio's Cyclically Adjusted FCF per Share too high?
Vaxil Bio's current Cyclically Adjusted FCF per Share is $-0.44. Overall, Vaxil Bio has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Vaxil Bio's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Vaxil Bio's Cyclically Adjusted FCF per Share of $-0.44 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Vaxil Bio and its competitors. Vaxil Bio's current Cyclically Adjusted FCF per Share is $-0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxil Bio stock overvalued right now?
Vaxil Bio (VXLLF) has a current Cyclically Adjusted FCF per Share of $-0.44. The current Cyclically Adjusted FCF per Share is $-0.44. Vaxil Bio's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Vaxil Bio (VXLLF), the current Cyclically Adjusted FCF per Share is $-0.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaxil Bio Business Description

Other Exchanges VXL:Canada
Address 559 Briar Hill Avenue, Toronto, ON, CAN, M5N 1N1
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
36GF Score

Get the complete analysis for VXLLF

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.04
Price